National Pension Service increased its position in shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) by 8.9% during the third quarter, Holdings Channel reports. The fund owned 52,106 shares of the biopharmaceutical company’s stock after buying an additional 4,240 shares during the period. National Pension Service’s holdings in Regeneron Pharmaceuticals were worth $20,948,000 as of its most recent filing with the SEC.

Other hedge funds also recently added to or reduced their stakes in the company. IFP Advisors Inc raised its position in shares of Regeneron Pharmaceuticals by 32.3% in the second quarter. IFP Advisors Inc now owns 328 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 80 shares in the last quarter. Advisory Services Network LLC raised its position in shares of Regeneron Pharmaceuticals by 5,433.3% in the second quarter. Advisory Services Network LLC now owns 332 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 326 shares during the period. Fuller & Thaler Asset Management Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $140,000. Brave Asset Management Inc purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $157,000. Finally, CIBC World Markets Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $202,000. Institutional investors own 68.26% of the company’s stock.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) traded down 0.90% during midday trading on Wednesday, hitting $383.78. The stock had a trading volume of 180,020 shares. The firm has a 50 day moving average price of $381.52 and a 200-day moving average price of $389.62. The stock has a market cap of $40.23 billion, a PE ratio of 55.99 and a beta of 1.79. Regeneron Pharmaceuticals Inc. has a 52-week low of $325.35 and a 52-week high of $565.68.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, November 4th. The biopharmaceutical company reported $3.13 earnings per share for the quarter, topping the consensus estimate of $2.73 by $0.40. The company had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.29 billion. Regeneron Pharmaceuticals had a return on equity of 21.51% and a net margin of 16.52%. The firm’s revenue for the quarter was up 7.3% compared to the same quarter last year. During the same period last year, the firm earned $3.47 EPS. Equities analysts predict that Regeneron Pharmaceuticals Inc. will post $11.73 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Regeneron Pharmaceuticals Inc. (REGN) Position Boosted by National Pension Service” was originally posted by Financial Market News and is the propert of of Financial Market News. If you are accessing this report on another domain, it was illegally copied and republished in violation of United States & international copyright & trademark law. The legal version of this report can be read at http://www.financial-market-news.com/regeneron-pharmaceuticals-inc-regn-position-boosted-by-national-pension-service/1210685/.

REGN has been the subject of several analyst reports. Robert W. Baird restated a “neutral” rating and set a $448.00 target price on shares of Regeneron Pharmaceuticals in a report on Friday, September 23rd. Goldman Sachs Group Inc. restated a “buy” rating and set a $521.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 27th. JPMorgan Chase & Co. set a $440.00 target price on Regeneron Pharmaceuticals and gave the company a “hold” rating in a report on Sunday, November 6th. Vetr cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $473.05 target price for the company. in a report on Monday, August 15th. Finally, Cowen and Company set a $430.00 target price on Regeneron Pharmaceuticals and gave the company a “hold” rating in a report on Sunday, November 6th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and twelve have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $468.87.

In other news, Director Joseph L. Goldstein sold 2,125 shares of the stock in a transaction dated Monday, November 14th. The shares were sold at an average price of $450.00, for a total transaction of $956,250.00. Following the sale, the director now directly owns 15,125 shares of the company’s stock, valued at approximately $6,806,250. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Arthur F. Ryan sold 2,000 shares of the stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $429.34, for a total transaction of $858,680.00. Following the sale, the director now directly owns 36,500 shares in the company, valued at $15,670,910. The disclosure for this sale can be found here. Company insiders own 10.40% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

5 Day Chart for NASDAQ:REGN

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc. (NASDAQ:REGN).

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.